International review of the utilisation and cost of percutaneous transluminal coronary angioplasty

被引:0
作者
Lecomte P. [1 ]
McKenna M. [1 ]
Kennedy L. [1 ]
Den Hartog M. [2 ]
Curry A. [1 ]
Rothman M. [3 ]
机构
[1] Lewin Group, Egham
[2] Lewin Group, Hoofddorp
[3] Cardiac Research and Development Office, London Chest Hospital, London
来源
The European Journal of Health Economics (HEPAC) | 2001年 / 2卷 / 3期
关键词
Angioplasty; Cost; Percutaneous transluminal coronary angioplasty; Review; Trend; Utilisation;
D O I
10.1007/s101980100068
中图分类号
学科分类号
摘要
We reviewed information published between 1990 and March 2001 to ascertain trends in the utilisation of percutaneous transluminal coronary angioplasty (PTCA) and to determine the availability of cost data. Our review encompassed Australia, Canada, France, Germany, Italy, Sweden, the United Kingdom, and the United States. The number of PTCAs increased in all countries studied during the 1990s. While the rate of PTCA use in all European countries lags behind that of the US, Germany and France are approaching the US rate, and the uptake of PTCA among European countries is increasing rapidly after a slow start. With regard to PTCA cost data, direct international comparisons are difficult since patient populations, methodological factors, and the timing and location of each study contributed to the differences observed between and within the studies reviewed. The increasing number of patients receiving PTCA emphasises the need for accurate cost data.
引用
收藏
页码:118 / 127
页数:9
相关论文
共 78 条
[1]  
Goodman C., The moving target problem and other lessons from percutaneous transluminal coronary angioplasty, pp. 123-140, (1996)
[2]  
Windecker S., Maler-Rudolph W., Heyndrickx G., Et al., Interventional cardiology in Europe 1995, Eur Heart J, 20, pp. 484-495, (1999)
[3]  
(2000)
[4]  
Waters A.-M., Armstrong T., Senes-Ferrari S., (1998)
[5]  
Aristides M., Gliksman M., Rajan N., Et al., Effectiveness and cost effectiveness of single bolus treatment with abciximab (ReoPro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients, Heart, 79, pp. 12-17, (1998)
[6]  
Eccleston D.S., Eisenberg M.J., Funding of coronary angioplasty in public hospitals, Aust N Z J Med, 26, pp. 430-431, (1996)
[7]  
Tu J.V., Pashos C.L., Naylor C.D., Et al., Use of cardial procedures and outcomes in elderly patients with myoacardial infarction in the United States and Canada, N Engl J Med, 336, pp. 1500-1505, (1997)
[8]  
(1997)
[9]  
Riviere M., Wang S., Leclerc C., Et al., Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada, Can Med Assoc J, 156, pp. 991-997, (1997)
[10]  
Zowall H., Coupal L., Fraser R.D., Et al., Economic impact of HIV infection and coronary heart disease in immigrants to Canada, Can Med Assoc J, 147, pp. 1163-1172, (1992)